Alta Fox Corrects Daktronics' Misleading and Nonsensical Version of Events
The Company's recent statement regarding Alta Fox's convertible note is nothing more than a desperate attempt to shift attention away from its own failures. This is a Board that appears to be doing everything in its power to cling to control at the expense of shareholders.
Alta Fox remains convinced that Daktronics is meaningfully undervalued – as evidenced by our significant investment in the Company. Instead of investing alongside shareholders, the Board and management team have been net sellers and collectively own less than 2.5% of the Company, a stark contrast to Alta Fox's conviction in the business.
At the Company's request, we previously entered into negotiations regarding the potential retirement of our convertible promissory note. We never entertained the idea of selling our entire economic stake in Daktronics. Instead, we were open to a reasonable compromise that would have retired a portion of our stake in exchange for immediate and substantive governance reforms to improve the Board's oversight and alignment with shareholders. At no point during these talks did Daktronics offer fair market value for our shares, nor did it propose any meaningful governance enhancements. When we rejected the Company's offers as insufficient, the Board called a Special Meeting of Shareholders to reincorporate in Delaware and eliminate cumulative voting – a brazen attempt to diminish Alta Fox's voice and something it had threatened to do during our negotiations.
Daktronics' version of events is not only incorrect – it is also nonsensical. The Board is attempting to convince shareholders that we do not believe in the Company's upside even though we are its largest shareholder and have been net buyers of its shares since investing in 2022. The Company is also insinuating that we were desperately seeking liquidity, ignoring the inconvenient fact that negotiations about repurchasing our holdings were initiated at the Board's request. At the same time, the Board is alleging that we rejected a fair offer to retire our convertible note. These statements contradict each other, revealing the Company's latest attempt to mislead shareholders.
The Board's lack of financial sophistication and basic understanding of the conversion value of our note was apparent during our negotiations. If we truly desired liquidity, we could have sold any amount of stock at a material gain over the last two-plus years. Instead, we have held our stake because of our belief that Daktronics still trades at a discount to its intrinsic value – a trading gap that we believe is caused by the Board's worst-in-class governance and mismanagement of the Company.
We believe there was a path to a win-win-win solution in which the Board would have been meaningfully strengthened, the Company could have used excess cash to avoid diluting shareholders and Alta Fox would have sacrificed some future upside in exchange for much-needed immediate governance improvements. Instead, the Board adopted an irrational bad faith negotiating position by demanding that Alta Fox accept a discount to the market value of our convertible promissory note. Now, the Board has resorted to attacking its largest investor – even as a growing chorus of other shareholders express their disapproval of its worst-in-class governance practices.
We urge our fellow shareholders to ignore Daktronics' blatant attempts to distract from the real issues: long-term underperformance, poor governance and a leadership team solely focused on self-preservation. In our view, the incumbent Board cannot be trusted to act in shareholders' best interests based on its lengthy history of rejecting governance best practices and its most recent attempt to stifle shareholder rights. Alta Fox looks forward to providing investors the opportunity to block the Board's latest anti-shareholder maneuver at the upcoming Special Meeting.
***
Alta Fox encourages Daktronics stakeholders to visit to review our presentation exposing how poor governance and a private family business mentality have driven massive underperformance for shareholders.
About Alta Fox
Founded in 2018 by Connor Haley, Alta Fox is a Texas-based alternative asset management firm that employs a long-term focused investment strategy to pursue exceptional risk-adjusted returns for a diverse group of institutions and qualified individual clients. Alta Fox focuses on identifying often overlooked and under-the-radar opportunities across asset classes, market capitalization ranges and sectors. Learn more by visiting www.AltaFoxCapital.com.
Certain Information Concerning the Participants
Alta Fox Opportunities Fund, LP ('Alta Fox Opportunities'), together with the other participants named herein (collectively, 'Alta Fox'), has filed a preliminary proxy statement and an accompanying BLUE proxy card with the Securities and Exchange Commission ('SEC') and intends to solicit votes in connection with their opposition to proposals to be presented at a special meeting of shareholders of Daktronics, Inc., a South Dakota corporation (the 'Company').
ALTA FOX STRONGLY ADVISES ALL SHAREHOLDERS OF THE COMPANY TO READ THE PROXY STATEMENT AND OTHER PROXY MATERIALS, INCLUDING ITS BLUE PROXY CARD, AS THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. SUCH PROXY MATERIALS WILL BE AVAILABLE AT NO CHARGE ON THE SEC'S WEB SITE AT . IN ADDITION, THE PARTICIPANTS IN THIS PROXY SOLICITATION WILL PROVIDE COPIES OF THE PROXY STATEMENT WITHOUT CHARGE, WHEN AVAILABLE, UPON REQUEST. REQUESTS FOR COPIES SHOULD BE DIRECTED TO THE PARTICIPANTS' PROXY SOLICITOR. HTTP://WWW.SEC.GOV
The participants in the proxy solicitation are expected to be Alta Fox Opportunities, Alta Fox GenPar, LP ('Alta Fox GP'), Alta Fox Equity, LLC ('Alta Fox LLC'), Alta Fox Capital Management, LLC ('Alta Fox Capital') and P. Connor Haley (collectively, the 'Participants').
As of the date hereof, Alta Fox Opportunities directly beneficially owns 5,933,019 shares of Common Stock, no par value (the 'Common Stock'), of the Company. Alta Fox Capital, as the investment manager of Alta Fox Opportunities, may be deemed to beneficially own the 5,933,019 shares of Common Stock beneficially owned by Alta Fox Opportunities. Alta Fox GP, as the general partner of Alta Fox Opportunities, may be deemed to beneficially own the 5,933,019 shares of Common Stock beneficially owned by Alta Fox Opportunities. Alta Fox LLC, as the general partner of Alta Fox GP, may be deemed to beneficially own the 5,933,019 shares of Common Stock beneficially owned by Alta Fox Opportunities. Mr. Haley, as the sole owner, member and manager of each of Alta Fox Capital and Alta Fox LLC, may be deemed to beneficially own the 5,933,019 shares of Common Stock beneficially owned by Alta Fox Opportunities.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
The information herein contains 'forward-looking statements.' Specific forward-looking statements can be identified by the fact that they do not relate strictly to historical or current facts and include, without limitation, words such as 'may,' 'will,' 'expects,' 'intends,' 'believes,' 'anticipates,' 'plans,' 'estimates,' 'projects,' 'potential,' 'targets,' 'forecasts,' 'seeks,' 'could,' 'should' or the negative of such terms or other variations on such terms or comparable terminology. Similarly, statements that describe our objectives, plans or goals are forward-looking. Forward-looking statements relate to future events or future performance and involve known and unknown risks, uncertainties, and other factors that may cause actual results, levels of activity, performance or achievements or those of the industry to be materially different from those expressed or implied by any forward-looking statements. Daktronics, Inc., a South Dakota corporation, has also identified additional risks relating to its business in its public filings with the Securities and Exchange Commission (the 'SEC'). Alta Fox Capital Management, LLC (together with its affiliates, 'Alta Fox'), has based these forward-looking statements on current expectations, assumptions, estimates, beliefs, and projections. While Alta Fox believes these expectations, assumptions, estimates, and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which involve factors or circumstances that are beyond Alta Fox's control. There can be no assurance that any idea or assumption herein is, or will be proven, correct. If one or more of the risks or uncertainties materialize, or if the underlying assumptions of Alta Fox described herein prove to be incorrect, the actual results may vary materially from outcomes indicated by these statements. Accordingly, forward-looking statements should not be regarded as a representation by Alta Fox that the future plans, estimates or expectations contemplated will ever be achieved. You should not rely upon forward-looking statements as a prediction of actual results and actual results may vary materially from what is expressed in or indicated by the forward-looking statements. Except to the extent required by applicable law, Alta Fox will not undertake and specifically declines any obligation to disclose the results of any revisions that may be made to any projected results or forward-looking statements herein to reflect events or circumstances after the date of such projected results or statements or to reflect the occurrence of anticipated or unanticipated events.
Certain statements and information included herein have been sourced from third parties. Alta Fox does not make any representations regarding the accuracy, completeness or timeliness of such third party statements or information. Except as may be expressly set forth herein, permission to cite such statements or information has neither been sought nor obtained from such third parties. Any such statements or information should not be viewed as an indication of support from such third parties for the views expressed herein.
Alta Fox Investor Relations
or
Okapi Partners
Bruce Goldfarb / Chuck Garske, 212-297-0720
[email protected]
For Media:
Longacre Square Partners
Kate Sylvester / Bela Kirpalani, 646-386-0091
[email protected]
INDUSTRY KEYWORD: PROFESSIONAL SERVICES FINANCE
SOURCE: Alta Fox Capital Management, LLC
Copyright Business Wire 2025.
PUB: 02/06/2025 05:30 PM/DISC: 02/06/2025 05:30 PM
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
Why Rocket Lab (RKLB) Stock Is Falling Today
What Happened? Shares of aerospace and defense company Rocket Lab (NASDAQ:RKLB) fell 8.8% in the afternoon session after investors took some profits off the table as markets awaited signals on future monetary policy from the Federal Reserve's Jackson Hole symposium later in the week. The downturn in the market was largely attributed to a significant sell-off in megacap tech and chipmaker shares. Nvidia, Advanced Micro Devices (AMD), and Broadcom all saw notable drops, dragging down the VanEck Semiconductor ETF. Other major tech-related companies like Tesla, Meta Platforms, and Netflix were also under pressure. A key reason for this trend is that much of the recent market gains have been concentrated in the "AI trade," which includes these large technology and semiconductor companies. So this could also mean that some investors are locking in some gains ahead of more definitive feedback from the Fed. The shares closed the day at $40.91, down 9% from previous close. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Rocket Lab? Access our full analysis report here, it's free. What Is The Market Telling Us Rocket Lab's shares are extremely volatile and have had 74 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The previous big move we wrote about was 7 days ago when the stock gained 4.9% on the news that an in-line inflation report fueled hopes for interest rate cuts and the U.S. and China agreed to extend their tariff truce. The Consumer Price Index (CPI), a key measure of inflation, came in largely as expected, holding steady at 2.7% year-over-year. This reading boosted investor optimism that the Federal Reserve will have room to lower interest rates at its next meeting, which could reduce borrowing costs for companies and consumers. Adding to the positive sentiment, the U.S. and China extended their tariff truce for another 90 days. This development alleviates concerns about renewed trade tensions, which is a significant relief for industrial companies reliant on global supply chains and international sales. Together, these events create a favorable outlook for economic growth, benefiting cyclical sectors like industrials. Rocket Lab is up 63.9% since the beginning of the year, but at $40.92 per share, it is still trading 20.4% below its 52-week high of $51.39 from July 2025. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
25 minutes ago
- Yahoo
Cantor Reaffirms Overweight on CyberArk (CYBR), $470 PT After Q2 Results
CyberArk Software Ltd. (NASDAQ:CYBR) is one of the On August 15, Cantor Fitzgerald analyst Jonathan Ruykhaver reiterated an Overweight rating on the stock with a $470.00 price target. The reiteration follows the company's early release of its second-quarter 2025 results. Cantor noted how CyberArk's second-quarter results have been steady but that it didn't provide any guidance update due to the pending acquisition by Palo Alto Networks. The proposed acquisition, valued at $25 billion, will enhance Palo Alto's platform by leveraging CyberArk's best-in-class PAM and agentic identity capabilities. 'The deal strategically enhances Palo Alto's platform by adding CyberArk's best-in-class PAM and agentic identity capabilities, bolstering its identity security and AI-driven SecOps offerings. While regulatory scrutiny and integration risks exist given the scale and cultural differences, the acquisition aligns with broader industry consolidation and Palo Alto's goal to expand its platform and customer base.' A successful investor looking out the window of a high rise office building, symbolizing the success of the company. CyberArk Software Ltd. (NASDAQ:CYBR) develops, markets, and sells software-based identity security solutions and services. While we acknowledge the potential of CYBR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None.
Business Wire
27 minutes ago
- Business Wire
TNF Pharmaceuticals Strengthens Financial Position for Growth and Value Creation
NEW YORK--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) ('TNF' or the 'Company'), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, today announced that is has significantly improved its financial position over the past 5 months through a material reduction in liabilities, while maintaining total assets of over $17 million as of June 30, 2025. 'The recent significant improvement in our financial position gives TNF a stronger platform for growth opportunities and taking advantage of shareholder value creation opportunities,' said TNF President and Chief Medical Officer, Mitchell Glass, M.D. 'We are pleased to have the continued support of our largest investors, and look forward to updating investors on TNF's business developments in the near future, including our ongoing collaboration with Renova on GLP-induced inflammation and muscle damage.' The improvements in the Company's financial position will be reflected in future financial statements of the Company. About TNF Pharmaceuticals, Inc. TNF Pharmaceuticals, Inc. (Nasdaq: TNFA), a clinical stage pharmaceutical company committed to extending healthy lifespan, is focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms. Isomyosamine is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-α, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. Isomyosamine is being developed to treat diseases and disorders marked by acute or chronic inflammation. The Company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy. Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve upon the rapidly growing CBD market, which includes both FDA approved drugs and CBD products not currently regulated as drugs. For more information, visit Cautionary Statement Regarding Forward-Looking Statements This press release may contain forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any expected future results, performance, or achievements. Forward-looking statements speak only as of the date they are made and neither the Company nor its affiliates assume any duty to update forward-looking statements. Words such as 'anticipate,' 'believe,' 'could,' 'estimate,' 'expect,' 'may,' 'plan,' 'will,' 'would'' and other similar expressions are intended to identify these forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, without limitation: unanticipated financial setbacks, the Company needing to pursue financing options that could adversely impact our liabilities due to adverse market conditions, the Company's ability to maintain compliance with the Nasdaq Stock Market's listing standards; the timing of, and the Company's ability to, obtain and maintain regulatory approvals for clinical trials of the Company's pharmaceutical candidates; the timing and results of the Company's planned clinical trials for its pharmaceutical candidates; the amount of funds the Company requires for its pharmaceutical candidates; increased levels of competition; changes in political, economic or regulatory conditions generally and in the markets in which the Company operates; the Company's ability to retain and attract senior management and other key employees; the Company's ability to quickly and effectively respond to new technological developments; and the Company's ability to protect its trade secrets or other proprietary rights, operate without infringing upon the proprietary rights of others and prevent others from infringing on the Company's proprietary rights. A discussion of these and other factors with respect to the Company is set forth in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, filed by the Company on April 11, 2025, and subsequent reports that the Company files with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and the Company disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise.
